<DOC>
	<DOCNO>NCT00113789</DOCNO>
	<brief_summary>This trial provide data safety efficacy pegfilgrastim , term duration grade 4 neutropenia , administer last day day multi-day , myelosuppressive chemotherapy regimen ovarian cancer .</brief_summary>
	<brief_title>Evaluating Pegfilgrastim Multi-Day Topotecan Regimen Subjects With Relapsed Refractory Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Subjects histologically confirm primary peritoneal carcinoma , epithelial ovarian cancer , tubal carcinoma relapse refractory 1 2 prior regimen therapy Measurable evaluable disease GOG Performance Status 0 2 Subjects must least 2 week major surgery recover associated toxicity sequelae At least 2 week radiation therapy recover associated toxicity Adequate hemopoietic function evidence : *ANC great 1.5 x 10^9/L , *platelets great 100 x 10^9/L *hemoglobin great equal 10 g/dL AST ALT le 1.5 x ULN ; total serum bilirubin less equal 2.0 mg/dL ; serum creatinine less equal 1.5 mg/dL calculate creatinine clearance great equal 60 mL/min Epithelial ovarian tumor low malignant potential Prior therapy topotecan Active infection require treatment systemic ( intravenous oral ) antiinfectives ( antibiotic , antifungal , antiviral agent ) within 72 hour chemotherapy Prior malignancy within last 5 year , exception surgically cure basal/squamous skin cell carcinoma , and/or carcinoma cervix insitu History impair cardiac status ( e.g. , severe heart disease , cardiomyopathy , congestive heart failure ) Any premalignant myeloid condition malignancy myeloid characteristic ( e.g. , myelodysplastic syndrome , acute chronic myelogenous leukemia Subject pregnant ( e.g. , positive HCG test ) breast feed Subject childbearing potential agree use adequate contraceptive precaution Any psychiatric , addictive kind disorder compromise ability subject give write informed consent and/or comply study protocol procedures Other investigational procedure exclude . Subject currently enrol , yet complete least 30 day since end another investigational device drug trial ( ) receive investigational agent ( )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>topotecan</keyword>
	<keyword>neutropenia</keyword>
	<keyword>NeulastaÂ®</keyword>
</DOC>